Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Change in Cash (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Change in Cash data on record, last reported at -$14.5 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 137.12% year-over-year to -$14.5 million; the TTM value through Dec 2025 reached -$37.3 million, down 150.63%, while the annual FY2025 figure was -$37.3 million, 150.63% down from the prior year.
  • Change in Cash reached -$14.5 million in Q4 2025 per PLSE's latest filing, down from -$11.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $54.4 million in Q3 2022 and bottomed at -$15.9 million in Q1 2022.
  • Average Change in Cash over 5 years is $3.4 million, with a median of -$7.5 million recorded in 2022.
  • The widest YoY moves for Change in Cash: up 4813.99% in 2021, down 348.04% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$13.4 million in 2021, then surged by 40.02% to -$8.0 million in 2022, then increased by 24.95% to -$6.0 million in 2023, then skyrocketed by 747.82% to $39.0 million in 2024, then tumbled by 137.12% to -$14.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$14.5 million in Q4 2025, -$11.1 million in Q3 2025, and -$12.9 million in Q2 2025.